Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial)

Recruiting N/A Interventional Study
Coronary Artery Disease Chronic Coronary Syndrome Acute Coronary Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
19 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
2,100 (estimated)
Sponsor
Samsung Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The AIM-FFR trial is a prospective, multi-center, open-label, randomized controlled, non-inferiority trial. The current trial will evaluate non-inferiority of MPFFR-guided PCI, compared with invasive FFR-guided PCI in patients with coronary artery disease.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Subject must be at least 19 years of age 2. Eligible for coronary angiography and/or percutaneous coronary intervention. 3. Chronic coronary syndrome or acute coronary syndrome (non-culprit vessels only) 4. Coronary artery disease in one or more native major epicardial vessel…
Contacts

Joo Myung Lee, MD, MPH, PhD

0234102575

drone80@hanmail.net

CONTACT

Seung Hun Lee, MD, PhD

821064137449

lsh8602@naver.com

CONTACT